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Abstract
Introduction Menopausal hormone therapy (HT) is typically
withheld from breast cancer survivors because of concerns
about risk for recurrence. Our objectives were to estimate the
effects of HT on recurrence in breast cancer survivors and to
examine the reliability of these estimates.
Methods In a systematic review of the literature we identified all
reports of HT use in breast cancer survivors that included
comparison groups. Study design features that might affect
selection of participants, detection of recurrence, and
manuscript publication were assessed. The relative risks for
breast cancer recurrence associated with HT were combined
with random effects models.
Results Two randomized and eight observational studies
included 1,316 breast cancer survivors who used HT and 2,839
nonusers. In the observational studies, HT users were younger
and more commonly node negative; only two reported balanced
restaging for HT and control groups. Randomized trials suggest
that HT increased the risk for recurrence (relative risk 3.41, 95%
confidence interval 1.59–7.33), whereas observational studies
suggest that HT decreased this risk (relative risk 0.64, 95%
confidence interval 0.50–0.82).
Conclusion Results from observational studies of HT
conducted in breast cancer survivors are discrepant with results
from randomized trials. Observational studies of HT use in
breast cancer survivors have design limitations that cannot be
controlled for using standard statistical methods. Therefore, the
randomized clinical trial data provide the only reliable estimates
of the effect of HT use on recurrence risks in breast cancer
survivors.
Introduction
Most breast cancer survivors are menopausal either at diagno-
sis or as a result of premature therapy-induced menopause,
and they frequently experience climacteric symptoms [1].
Menopausal hormone therapy (HT), either with estrogen alone
or with combined estrogen and progestin, relieves estrogen
deficiency symptoms [2] but it is commonly withheld from
women with diagnosed breast cancer because of concerns
regarding an increased risk for recurrence [3].
The available data from observational studies indicate that use
of HT is associated with increased risk for breast cancer [4].
In postmenopausal women, the randomized Women's Health
Initiative HT trials found an increased risk for breast cancer
with estrogen plus progestin [5] but not with unopposed
estrogen [6]. An apparent reduction in risk seen during the first
2 years of combination HT was attributed to a masking of
breast cancer detection, with a higher risk for more advanced
breast cancers subsequently [5]. In breast cancer survivors,
observational studies have consistently reported similar or
lower risks for recurrence among women using HT as com-
pared with nonusers [7], albeit with methodological weak-
nesses [8]; this has been interpreted as evidence of the safety
or perhaps benefit of HT in women with breast cancer. How-
ever, the first large randomized trial in this population reported
that HT significantly increased the risk for recurrence [9].
The objectives of this meta-analysis were to estimate the
impact HT has on recurrence risk among observational and
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randomized studies, and to examine the reliability of these
estimates.
Materials and methods
A previous Medline search from 1966 to 1999 [7] was
updated to February 2004 using the medical subject headings
'breast neoplasm', 'neoplasm recurrence', 'estrogens', 'estro-
gen replacement therapy', 'hormone replacement therapy',
and 'estradiol', and reference lists of abstracted manuscript
and protocols were reviewed. Only studies that included
women with invasive breast cancer who received oral HT, that
had an explicitly defined comparison group, and that reported
breast cancer recurrences were included. Studies that
reported overlapping or redundant data were excluded [10-
16], as were those that did not adequately describe the selec-
tion or composition of control groups [17,18] or that included
only topical hormones [19].
Two of the authors (NFC and JAK) independently abstracted
data on the following variables: sample size, age at diagnosis
and at trial induction, tumor stage, nodal status, estrogen and
progesterone receptor status, disease-free interval (DFI)
between initial breast cancer diagnosis and initiation of HT,
type and duration of HT used, follow up after initiation of HT,
and number and timing of breast cancer recurrences.
Each study was systematically reviewed for features that could
introduce bias, including procedures for identifying partici-
pants, whether institutional review board approval and/or
informed consent was obtained, whether risk factors for recur-
rence were similar at diagnosis, and whether restaging before
entry (to exclude metastatic disease) and duration of follow up
were similar for HT users and nonusers. Observational studies
were classified as 'clinical experiences' if one or more study
authors provided health care to the cohort with potential par-
ticipation in the decision to use HT.
When not reported, the follow up after HT initiation was
assumed to equal the duration of HT use. Any second breast
cancer event (local, regional, or distant recurrence or invasive
cancer in either breast) was treated as a recurrence because
studies did not consistently make these distinctions.
Relative risk (RR) and 95% confidence interval (CI) were cal-
culated for each study for the recurrence rate and mortality
rate among HT users and nonusers. A random effects model
was used to estimate the combined RR for randomized and
observational studies using Meta-Analyst [13].
Results
Ten studies were identified, including a total of 1,316 breast
cancer survivors who used HT and 2,839 who did not. Of
these 10 studies, two were unblinded randomized controlled
trials without placebo arms [9,20], one began as a randomized
trial but was reported as an observational study and is consid-
ered as such here, and seven were observational studies.
Summary of randomized trials
Both randomized trials were conducted in Europe (one in Eng-
land and one in Sweden). They involved a total of 445 patients
with a mean age of 55.5 years, a mean DFI of 33.2 months, a
duration of HT use of 19.9 months, and a mean follow-up
period after HT initiation of 25.2 months (Table 1). A total of
36 recurrences and nine deaths occurred during this time in
these trials; the pooled RR for the two randomized trials was
3.41 (95% CI 1.59–7.33).
Summary of observational studies
Of the eight observational studies, six were clinical experi-
ences [22-27]. The eight studies involved a total of 3710
patients with a mean age of 59.7 years, a mean DFI of 49.2
months, a duration of HT use of 28 months, and a mean follow-
up period after HT initiation of 57.1 months (Table 1). A com-
bined total of 552 recurrences (109 among HT users) and
460 deaths (51 among HT users) occurred in these trials. The
pooled RR for the observational studies was 0.64 (95% CI
0.50–0.82).
All studies
Most studies included both combination HT and unopposed
estrogens without stratifying risk estimates according to prep-
aration. Three of the observational studies [22,24,25] reported
obtaining informed consent but only from women who used
HT. Three studies [20,24,26] reported similar restaging for
treatment and control groups at the beginning of the observa-
tion period, although one of these [26] did not report whether
those found to have occult metastasis were excluded. Not all
studies reported the DFI for the control groups, but several
reported matching control individuals according to DFI
[22,27]. Prognostic factors for HT users and nonusers differed
in most studies (Table 1). On average, HT users were more
than 3 years younger than nonusers and were more likely to be
node negative. The average duration of HT use was 26.6
months, with an average duration of follow up after initiation of
HT of 53 months. The mean DFI was 36.9 months for HT users
and 55.6 for nonusers.
Among the 1,191 HT users in nine studies reporting recur-
rences, 137 (11.7%) experienced a recurrence of their breast
cancer during follow up. Among the 2,477 nonusers in these
studies, 451 (18.2%) had a recurrence. The average annual
recurrence rate was 3.3% (range 0.6–7.1%), with substan-
tially higher rates in the randomized trials. Combining all stud-
ies yielded a RR for recurrence of 0.84 (95% CI 0.54–1.3; Fig.
1), with statistically significant heterogeneity (Q = 25.3).
Discussion
Estimates from observational studies of HT among breast can-
cer survivors suggest that HT prevents breast cancerAvailable online http://breast-cancer-research.com/content/7/4/R535
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Table 1
Characteristics of 1316 users and 2839 nonusers of hormone therapy
Study Treatment n Mean age 
(years)
Stage Nodal 
status
ER status PgR status Mean DFI 
before 
HT 
(months)
Estrogen alone 
(%)
Mean 
duration of 
HT 
(months)
Mean follow-
up after 
HT 
(months)
Recurrences 
(n)
Deaths, all 
cause 
(n)
Deaths, primary 
tumor (n)
Randomized trials
Marsden et 
al. (2000; 
n = 100) 
[20]
HT 51a 58b NR NR NR NR 40b NR 6 NR 2 NR NR
No HT 49a 55b NR NR NR NR 36b NR 1 NR NR
Holmberg et 
al. (2004; 
n = 345) 
[9]
HT 174 55.5 NR 25.9% (38) 
positive
86 
positivec
NR 31.2b NR 24 25.2b 26 5 3
No HT 171 55.0 NR 21.4% (31) 
positive
73 
positivec
NR 32.4b 25.2b 74 4
Observational studies
Ursic-Vrscaj 
and Bebar 
(1999; n 
= 63) [27]
HT 21d 47b 1 G1
10 G2
7 G3
14 
negative, 
7 
positive
5 positive, 
16 
negative
8 positive, 
13 
negative
62 4.8 28 38g 40 g 0
No HT 42d 48.2 7 G1
17 G2
11 G3
28 
negative 
14 
positive
18 positive, 
22 
negative
22 positive, 
18 
negative
NR 38g 51 g 1
DiSaia et al. 
(2000; n 
= 487) 
[22]
HT 125 55.7 17 DCIS
52 stage I
27 stage II
10 stage III
1 stage IV
NR NR NR 46b 28 22b 92.1g NR 4g NR
No HT 362 55.9 NR NR NR NR NR 90.6g NR 57g NR
O'Meara et 
al. (2001; 
n = 869) 
[36]
HT 174d 63.6e 91 stage I
51 stage II
20 stage I/
II
10 stage III
2 stage II/
III
128 
negative, 
31 
positive
84 positive, 
39 
negative
71 positive, 
45 
negative
47.7e 79 15b 44.4b,f 16 17 5
No HT 695d 63.6e 403 stage 
I
246 stage 
II
3 stage I/II
42 stage III
1 stage II/
III
470 
negative, 
175 
positive
409 
positive, 
137 
negative
311 
positive, 
206 
negative
47.7e 44.4b,f 101 115 59
Beckmann 
et al. 
(2001; n 
= 185) 
[24]
HT 64 NA 37 T1
19 T2
8 T3/4
44 
negative, 
20 
positive
31 positive, 
33 
negative
34 positive, 
30 
negative
0N A3 3 b 37b 64N R
No HT 121 NA 62 T1
42 T2
17 T3/4
76 
negative, 
45 
positive
48 positive, 
73 
negative
48 positive, 
73 
negative
04 2 b 17 15 NR
Marttunnen 
et al. 
(2001; n 
= 131) 
[26]
HT 88 53.4 3 DCIS
67 T1
17 T2
1 T3
72 
negative, 
10 
positive
57 positive, 
15 
negative
54 
positiveg, 
13 
negativeg
50.4 38.6 30 30 7 2 2
No HT 43 52.8 1 DCIS
29 T1
11 T2
2 T3
30 
negative, 
13 
positive
29 positive, 
9 
negative
30 
positiveg, 
7 
negativeg
50.4 31.2 5 3 3
Durna et al. 
(2002; n 
= 1122) 
[23]
HT 286 56.8b 180 stage 
I
64 stage II
22 stage 
III/IV
NA NR NR 12b 5.9 21b 69.6b 44 16 13
No HT 836 64.7b 470 stage 
I
191 stage 
II
120 stage 
III/IV
NA NR NR NR 61.2b 247 199 122Breast Cancer Research    Vol 7 No 4    Col et al.
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recurrence, whereas estimates from randomized trials suggest
the opposite. Because of statistically significant heterogeneity,
these estimates should not be combined. Although all of the
trials included in our analyses contained methodological weak-
nesses, the nonrandomized studies had design features that
could introduce selection, reporting, and/or publication
biases. The selection of healthier women to begin HT, the ben-
efit of restaging before initiation of HT, the short duration of HT
exposure and follow up, the potential effects of HT on mammo-
grams that could obscure the diagnosis of recurrent or new
breast cancers, and publication bias favoring publication and/
or completion of studies reporting a protective effect of HT
could explain the apparent protective effect of short-term HT
on recurrence among breast cancer survivors in these studies.
Systematic serial restaging with blood tests and imaging dur-
ing follow up is no longer generally recommended. However,
their use detects breast cancer recurrence earlier. Balanced
restaging was defined in only two out of seven observational
studies. If breast cancer survivors contemplating HT use were
more likely to have restaging, then the imbalance could
account for the apparent protective effect of HT in observa-
tional studies. Although the description of prognostic factors
was rarely complete, HT users in observational studies were
younger and had more favorable prognostic profiles than did
control individuals. This process also selected women with
severe vasomotor symptoms, who have lower estradiol and
testosterone levels; higher levels of these hormones have
been associated with increased breast cancer risk. As a result,
it is possible that women who were more likely to be offered
HT [20] had lower recurrence risks. It is important to note that
Vassilopoulo
u-Sellin et 
al. (2002; 
n = 299) 
[21]
HT 56h 56b 9 <1 cm
30 1–2.5 
cm
15 >2.5 
cm
35 
negative, 
13 1–3, 
6 >3
37 
negative
NR 105.6 100 30 >5 
years, 20 
2–5 years, 
6 2 years
71 2 1 0
No HT 243h 53b 38 <1 cm
134 1–2.5 
cm
67 >2.5 
cm
133 
negative, 
70 1–3, 
33 >3
164 
negative
NR 99.6 NR 33 2 1
Decker et al. 
(2003; n 
= 554) 
[25]
HT 277 57.4b 84 DCIS
124 stage 
I
47 stage 
IIA
19 stage 
IIB
3 stage 
IIIA
NR 100 
positive, 
54 
negative
63 positive, 
46 
negative
43.3 48.7 44.4 49.7 30 7 5
No HT 277 59.0b 84 DCIS
124 stage 
I
47 stage 
IIA
19 stage 
IIB
3 stage 
IIIA
NR 121 
positive, 
35 
negative
73 positive, 
42 
negative
NR 45.6 35 17 9
Summary
Randomized 
trials
HT 225 56.07 38 positive 86 positive 33.19 19.92 25.20 28 5 3
No HT 220 55.00 31 positive 73 positive 33.20 25.20 8 4 4
Observation
al studies
HT 1091 56.98 293 
negative, 
87 
positive
277 
positive, 
194 
negative
230 
positive, 
147 
negative
37.70 40.4 28.02 57.46 109 51 25
No HT 2619 60.87 737 
negative, 
350 
positive
625 
positive, 
440 
negative
484 
positive, 
346 
negative
54.01 57.02 443 409 195
All 
combined
HT 1316 56.82 293 
negative, 
125 
positive
363 
positive, 
194 
negative
230 
positive, 
147 
negative
36.93 40.4 26.58 53.03 137 56 28
No HT 2839 60.39 737 
negative, 
381 
positive
698 
positive, 
440 
negative
484 
positive, 
346 
negative
50.55 54.88 451 413 199
aExcluding stage III/IV patients. bMedian value. cRefers to hormone receptor status; specific data concerning estrogen receptor (ER) and 
progesterone receptor (PgR) status were not reported. dExcluding patients with ductal carcinoma in situ (DCIS). eWeighted mean. fFor recurrence 
only; follow-up for mortality was 55.2 months. gPersonal communication. hExcluding DCIS, stages III and IV, and ER-positive patients. DFI, disease-
free interval; HT, hormone therapy; NA, not able to calculate; NR, not reported.
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the majority of observational studies included in these analy-
ses were not designed as observational studies from the start
but rather as clinical experiences. Had these observational
studies been more rigorously designed, using modern epide-
miological techniques, many of these biases could have been
minimized.
The adverse effect of combined HT on mammographic breast
cancer detection [5] might have affected recurrence detec-
tion. Both recurrent and new breast cancers, which account
for 10–20% of cancer events in women with prior lumpec-
tomy, could have falsely appeared lower in HT users because
of HT-related interference with mammographic diagnosis.
However, this factor is probably not large, given the sharp
increase in risk observed even after short-term HT use in ran-
domized trials [36] and that the increase in risk pertained to
distant as well as local recurrences.
The randomized trial reported by Holmberg and colleagues [9]
overcomes many of the shortcomings of observational studies
and provides the best available data on the impact of HT in
breast cancer survivors. Although their unblinded design and
lack of a placebo group could result in selective attrition, fol-
low-up rates were comparable among HT users and nonusers.
These investigators also reported summary interim analyses of
a similar randomized trial, the Stockholm trial, with a relative
hazard ratio of 0.82 (95% CI 0.35–1.9). This trial was not
included in this analysis because its findings have not yet been
reported in full; the reasons for its discrepant findings are
unclear at this time.
Conclusion
Observational studies of HT use in breast cancer survivors
have design limitations that cannot be controlled for using
standard statistical methods and hence should be considered
essentially uninformative with respect to the safety of HT use
in breast cancer survivors. Only randomized clinical trials are
likely to provide reliable estimates of the effect of HT use in this
setting.
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Figure 1
Relative risks for recurrent breast cancer associated with hormone ther- apy (HT) Relative risks for recurrent breast cancer associated with hormone ther-
apy (HT). Each black circle indicates the relative risk for recurrent 
breast cancer; the horizontal lines indicate the 95% confidence interval 
(CI). The top portion of the figure describes randomized controlled tri-
als, the middle portion describes observational studies, and the bottom 
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